Mentor is being packaged for sale


Hearing Jnj and Galderma/Nestle have a meeting scheduled for next Thursday in Dallas. And no, it isn't to discuss the future of the M2VP program. This whole market is about to be turned on its head.
 









Soon. Word is JnJ is pruning down the MD&D segment and Cordis, Mentor, Acclarent, and Codman are all on the way out. Most likely to be announced before year end. The timing of JnJs purchase of Acclarent could not have come at a worse time.

The issue w Mentor right now is without a toxin it has been difficult to find an interested buyer and the value of Mentor has fallen well below the $1B JnJ paid.
 












Because both companies best days are behind them. Both have large market share,now competing w multiple competitors w differentiated products. Both are owned by larger conglomerates that have no idea how to run the business and have cut spending and cut funding. This is a huge issue. Both companies have reps who have relied on relationships and "howdy calls" and have no idea how to win in a competitive landscape.

Other than that, it's a great match.
 




Write your reply...